Discover a trial in which patients received either IL-2 or a placebo for 5 days, followed by weekly doses for 4 weeks.

As shown on the right, TES release the interleukin IL-2, which stimulates CAR-T cells to multiply, and anti-CD3 and anti-CD28, two antibodies that, similar to tumor antigens presented by an ...

Researchers discover a novel protein therapy that recharges exhausted T cells, unleashing their power to eradicate tumors and ...

Coya sees IL-2 as a molecule that can boost the number and power of regulatory T cells (Tregs), leading it to study it as a single agent, COYA 301, and pair the cytokine with the recombinant ...

This is achieved by preventing IL-2, either exogenous or secreted by effector T cells, from binding to trimeric receptors on regulatory T cells while still allowing IL-2 to bind and expand ...

These drugs are designed to deliver a double whammy to tumours, stimulating a local immune response with IL-2 via natural killer cells and cytotoxic T cells, and removing a brake on the immune ...

Discover a study that shows that modulating STAT6 directly may represent an innovative strategy for managing severe, ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Outpace Bio, a cell therapy company using unrivaled AI-powered protein design to program immune cells with improved efficacy against solid tumors, announced today that it will present new data on its ...